28.8 C
New York
Saturday, June 6, 2026

Tag: PDF

newssourceFORcompanyinformationcontent1marketreleases

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with...

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and AID Use

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

Oban BioPharma Announces Presentation of Late-Breaking Abstract at ADA 2026 Highlighting OBT-676: A First-in-Class Small Molecule Combining Dual Amylin and Calcitonin Receptor Full Agonism...

STAMFORD, Conn., June 05, 2026 (GLOBE NEWSWIRE) -- Oban BioPharma today announced that preclinical data for OBT-676, a lead small-molecule candidate for the treatment of obesity and type 2 diabetes, has been selected for a late-breaking presentation at the upcoming American Diabetes Association (ADA) 86th Scientific Sessions being held from June 5th-8th in New Orleans, LA. The study characterizes OBT-676 as a new molecular entity that achieves potent full agonism at the amylin and calcitonin receptors (DACRA) while simultaneously delivering partial agonism across the GLP-1, GIP, and glucagon (Triple-G) pathways. OBT-676 demonstrated significant reduction in food intake and adipose-selective weight loss in the industry-standard rat diet-induced obesity (DIO) model.

Food Safety Testing Market Expected to Reach $44.1 Billion by 2033, at a CAGR of 7% : Allied Market Research

Driven by intensifying food safety requirements with the increased stringency of regulatory guidelines, a substantial and growing incidence of food fraud across global supply...

Food Safety Testing Market Expected to Reach $44.1 Billion by 2033, at a CAGR of 7% : Allied Market Research

Driven by intensifying food safety requirements with the increased stringency of regulatory guidelines, a substantial and growing incidence of food fraud across global supply...

New data from Phase 2 ZUPREME-1 trial at the American Diabetes Association 2026 Scientific Sessions further support potential of petrelintide to redefine the weight...

Press release – No. 13 / 2026 

DBV Technologies to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

Châtillon, France, June 5, 2026

GAUMONT – Informations relatives au nombre total de droits de vote et d’actions du capital social au 31 mai 2026

GAUMONT

Programmers Paradise Announces StudyHQ for Android, Expanding Its Private Scan-to-PDF Organizer to Google Play

BUFORD, Ga., June 5, 2026 /PRNewswire/ -- Programmers Paradise LLC today announced the launch of StudyHQ for Android, bringing its private scan-to-pdf organizer and...

Smart Manufacturing Market worth $995.67 billion by 2032 – Exclusive Report by MarketsandMarkets™

DELRAY BEACH, Fla., June 5, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the Smart Manufacturing Market is projected to reach USD 995.67 billion by 2032 from...

Smart Manufacturing Market worth $995.67 billion by 2032 – Exclusive Report by MarketsandMarkets™

DELRAY BEACH, Fla., June 5, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the Smart Manufacturing Market is projected to reach USD 995.67 billion by 2032 from...

New Health Economic Evidence Shows Health & Cost Benefits When Starting Dialysis at Home

New UK economic analyses show improved patient outcomes and health system savings – including nearly £200 million in projected UK NHS savings over 5 years – through increased uptake of home-based peritoneal dialysis compared to in-center hemodialysis

Chiesi Global Rare Diseases Announces European Commission Approval of LOJUXTA® (lomitapide) ▼ Capsules for Paediatric Use in Homozygous Familial Hypercholesterolaemia (HoFH)

European Commission approval expands the indication of lomitapide in the European Union (EU) to include children 5 years of age and older with HoFH, an ultra-rare genetic disorder affecting LDL-cholesterol levels 
European Commission approval expands the indication of lomitapide in the European Union (EU) to include children 5 years of age and older with HoFH, an ultra-rare genetic disorder affecting LDL-cholesterol levels

Northeastern University Unveils GENESIS: First Agentic AI System to Take 5G/6G RAN Features from Specification to Over-the-Air in Hours

BOSTON, June 4, 2026 /PRNewswire/ -- Researchers at Northeastern University's Institute for Intelligent Networked Systems (INSI) have developed GENESIS, an agentic AI framework that automates...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPDF

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers